Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Claritin OTC Switch In Pediatric Populations Could Pose Concerns For NDAC

This article was originally published in The Tan Sheet

Executive Summary

FDA advisory committee members may be hesitant to favor an Rx-to-OTC switch of Schering-Plough's Claritin franchise for younger pediatric patients

You may also be interested in...

OTC Claritin Hatch/Waxman Exclusivity Not Expected By Schering-Plough

Schering-Plough does not expect to receive three years of Hatch/Waxman exclusivity for its supplemental NDAs for OTC Claritin (loratadine)

Second-Generation Antihistamine OTC Labeling Could Resemble Monograph

OTC labeling for second-generation antihistamines - if the drugs were to switch - may not differ greatly from warnings on existing nonprescription allergic rhinitis symptom relief drugs.

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts